Paolo Calabrò: Lower LDL-C Variability With PCSK9 Inhibitors and Inclisira
Paolo Calabrò, Director of the Cardiovascular Department at S. Anna and S. Sebastiano Hospital, shared on LinkedIn:
”Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy.”
Title: Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy
Authors: Arturo Cesaro, Vincenzo Acerbo, Francesco Scialla, Andrea Zito, Gennaro Porcelli, Domenico Panico, Giovanni Argenziano, Demetrio Iaria, Maria Grazia Monaco, Vincenzo De Sio, Felice Gragnano, Michele Golino, Massimiliano Ruscica, Stefano Carugo, Alberto Corsini, Paolo Calabrò
Read the full article here.
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 11:05Julius Kyei Baffour: Understanding Thrombophilia Testing and Patient Risk
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?